Curriculum Vitae
Federico Galvagni



Personal information

First name / Surname	**Federico Galvagni**
Current position	Associate Professor in Molecular Biology in the Department of Biotechnology Chemistry & Pharmacy of the University of Siena
Telephone(s)	Lab. +39 0577 234933 Off. +39 0577 232424
E-mail	federico.galvagni@unisi.it
Skype	federico.galvagni

Education and degrees obtained

- 2018 - National Scientific Qualification (art.16 of the law 30 December 2010, n.240) as associate professor in **General Biochemistry - 05/E1**
- 2017 - National Scientific Qualification (art.16 of the law 30 December 2010, n.240) as associate professor in **Molecular Biology - 05/E2**
- 2017 - National Scientific Qualification (art.16 of the law 30 December 2010, n.240) as associate professor in **Genetics - 05/I1**
- 2017 - National Scientific Qualification (art.16 of the law 30 December 2010, n.240) as associate professor in **General Biology - 05/F1**
- 2010 - MAGI Award from the International Association of Medical Genetics (MAGI Onlus).
- From 06/2022- present Associate Professor in Molecular Biology.
- Since 2005 to 06/2022 - Assistant professor in Molecular Biology (tenured position).
- From 2002 to 2005 – Assistant professor in Molecular Biology (with no tenure).
- From 1997 to 2002 – Research fellow with a temporary position (Assegno di ricerca).
- 1997 - PhD in Genetics at Padua University. Title of PhD-thesis:"Functional analysis of muscle-specific promoter of the human dystrophin gene".
- From 1993 to 1997 – PhD School in Genetics at Padua University (Telethon doctoral fellow)
- 1993 - Master of Science in Biological Sciences at University of Padova. Final mark: 110/110 Summa cum laude. Title of thesis: "Isolation and characterization of new DNA markers in the subtelomeric region of the X chromosome long arm".
- 1992 - Erasmus Stage at the Biochemistry Department of the Oxford University for the study of the organization of the long arm pseudoautosomal region of the human sex chromosomes.
- 1988 - High School Diploma in Classics at Liceo-Ginnasio "A. Rosmini" (Rovereto-TN).

Professional Experience and fellowships

- From 06/2022- present Associate Professor in Molecular Biology in the Department of Biotechnology Chemistry & Pharmacy of the University of Siena and Teacher of Molecular Biology courses.
- 2002 - 06/2022 Researcher in Molecular Biology in the Department of Biotechnology Chemistry & Pharmacy of the University of Siena and Teacher of Molecular Biology and Genetics courses.
- 2000 (Oct.-Dec.) - Guest researcher in the laboratory of Prof. F. Bussolino (Institute for Cancer Research and Care, IRCC, Turin) focusing on methodologies for the study of angiogenic factors.
- 2000 (August) - Guest researcher in the laboratory of Prof. E.F. Wagner (Research Institute of Molecular Pathology, Vienna) studying muscular regeneration in transgenic mice for AP-1 transcription factors.
- 1997 - 2002 Post-doctoral research fellowship in the Department of Molecular Biology of the University of Siena – Italy for the study of Utrophin gene transcriptional regulation.
- 1994 - 1996 Telethon Doctoral research fellowship for the study of the muscle-specific promoter of the dystrophin gene in the Department of Molecular Biology of the University of Siena - Italy.
- 1993 - 1994 Telethon Doctoral research fellowship for the study of the muscle-specific promoter of the Dystrophin gene in the Department of Biological sciences of the University of Padua - Italy.
- 1992 (Sept.-Dec.) Erasmus Internship, Biochemistry Department, Oxford University, in the laboratory of Prof. E. Southern, studying the organization of the long arm pseudoautosomal region of human sex chromosomes.

Principal research activities

- Since 2011 until today - He is studying oxidative stress response in retinal pigment epithelial cells and endothelial cells, both involved in neovascular retinal diseases. He is also studying the role of the transmembrane glycoprotein CD93 in angiogenesis process in tumors and age-related macular degeneration. He worked in the characterization of a monoclonal antibody for the inhibition of angiogenesis through CD93 binding. He studied the role of the transcription factors Snai1 and DNA methylation in the differentiation process of embryonic stem cells and muscle cells, and of the AP1 transcription factors in the adhesion of endothelial cells.
- From 2001 to 2013 - He acquired experience in field of angiogenesis by studying the angiogenic factors of the VEGF family and their receptors. From 1995 to 2002 - He studied the transcriptional regulation of the human Dystrophin and Utrophin gene for the Duchenne muscular dystrophy therapy, by means in vitro assays (generation of cosmid library, biochemical purification of transcription factors, EMSA assays, Footprinting assay, reporter plasmids transfection in muscle cells, qRT-PCR, recombinant proteins synthesis in vitro and in bacteria.
- From 1993 to 1994 - He performed a mutation analysis of the human Dystrophin gene.
- From 1992 to 1993 - He characterized the pseudo-autosomal region of the X chromosome long arm.

Sequences

AJ278913; Mus musculus partial gene for Utrophin, exon 2, strain 129/svj

Grants

- Formal collaborator of EURETINA Retinal Medicine Clinical Research 2020. Project title: The C-type lectin receptor CD93 as a new target in retinal vascular diseases.
- Principal Investigator FFABR - Fondo per il Finanziamento delle Attività Base di Ricerca- 2017.
- Principal Investigator and Scientific Coordinator of the programme COFIN-PRIN 2007. Project title: Study of transcription factors involved in endothelial development and maintenance of endothelial functionality.
- Research Unit Leader U.R. COFIN-PRIN 2004. Project title: Pathways and genes modulated by the high mobility group box 1 protein in angiogenesis.
- Participant of the research program Bando di Ricerca Sanitaria Finalizzata 2008 Cellule Staminali: Targeting MAP Kinases to eradicate the mammary cancer stem cell reservoir.
- Participant of the research program Bando per la Ricerca Regionale in Materia di Salute 2009: Identification of surface interaction between MYC and PIM1 for the screening of small molecules that interface with their transforming activity.
- Participant of the research program AIRC 2008: Role of VEGFs in vasculogenesis, angiogenesis and lymphangiogenesis.
- Participant of the research program ITT (Istituto Toscano Tumori) 2007: Myc and Pim1 Cooperation in Transcriptional Regulation and Chromatin Modifications leading to activation of Downsteam Effectors that Mediate Cell Transformation
- Participant of the research program AIRC 2005:Cellular response to VEGFs in vasculogenesis, angiogenesis and lymphangiogenesis.
- Participant of the research program PRIN 2003: inhibition of tumoral angiogenesis by means of "RNA interference".
- Participant of the research program PRIN 2002: Role of VEGF-D in angiogenesis and vasculogenesis.
- Participant of the research program AIRC 2002: Role of VEGF-D in angiogenesis and lymphangiogenesis and identification of new endothelial markers.
- Participant of the research program Telethon n. GP0275Y01: Utrophin regulation in muscle”
- Participant of the research program AIRC 2001: Angiogenic activity of Vascular Endothelial Growth Factor D.
- Participant of the European research program FP4-BIOMED 2 (Project ref erence: BMH4983380): Transgenic and somatic gene therapy studies of the role of the vascular endothelial growth factor (VEGF gene family) in normal and pathological blood vessel formatio
- Participant of the research program Telethon n. 970 (1997): transcriptional regulation of the dystrophin and utrophin genes in muscle cells.
- Participant of the research program AIRC 1995: cDNA cloning and characterization of cFOS induced genes.

Other activities

- Federico Galvagni is charter member, director and treasurer of the LymphoLab ONLUS (http://www.lympholab.org/), an association with the aim of promoting the knowledge and education in

the vascular and lymphatic field, and helping disadvantaged persons because of their physical conditions related to lymphatic and vascular disorders.

- Founding partner of the startup-spin-off of the University of Siena "UCme Bioscience" for the development of antiangiogenic biotechnological drugs.

- Filed patent: "Anti-CD93 antibody", IT application n° 102021000021764, International application n° P022524WO-01

- Reviewer for international peer-review Journals (Heliyon, Histology and Histopathology, Plos One, Molecular Biology of the Cell, Frontiers Pharmacology, Cells, International Journal of Molecular Sciences, Cellular and Molecular Life Sciences, Marine Drugs, Gene Reports, Cellular Physiology and Biochemistry, Journal of Cellular Physiology, JoVE, Neurological Sciences).

- External reviewer for PhD dissertations: Università di Pavia, Friedrich-Schiller-Universität Jena, Università di Torino.

- External Reviewer for Research Grant Applications: Università di Parma, Università di Padova

Publications

1) Barbera S, Raucci L, Tassone G, Tinti L, Prischi F, Santucci A, Mongiat M, Tosi GM, Galvagni F, Dimberg A, Pozzi C, Orlandini M. Dimerization of the C-type lectin-like receptor CD93 promotes its binding to Multimerin-2 in endothelial cells. Int J Biol Macromol. 2023;224:453-464.
2) Carullo G, Bottoni L, Pasquini S, Papa A, Contri C, Brogi S, Calderone V, Orlandini M, Gemma S, Varani K, Butini S, Galvagni F, Vincenzi F, Campiani G. Synthesis of Unsymmetrical Squaramides as Allosteric GSK-3β Inhibitors Promoting β-Catenin-Mediated Transcription of TCF/LEF in Retinal Pigment Epithelial Cells. ChemMedChem. 2022;17(24):e202200456.
3) Cicaloni V, Karmakar M, Frusciante L, Pettini F, Visibelli A, Orlandini M, Galvagni F, Mongiat M, Silk M, Nardi F, Ascher D, Santucci A, Spiga O. Bioinformatics Approaches to Predict Mutation Effects in the Binding Site of the Proangiogenic Molecule CD93. Front Bioinform. 2022;2:891553.
4) Bianchi L, Altera A, Barone V, Bonente D, Bacci T, De Benedetto E, Bini L, Tosi GM, Galvagni F, Bertelli E. Untangling the Extracellular Matrix of Idiopathic Epiretinal Membrane: A Path Winding among Structure, Interactomics and Translational Medicine. Cells. 2022;11(16):2531.
5) Elia I, Realini G, Di Mauro V, Borghi S, Bottoni L, Tornambè S, Vitiello L, Weiss SJ, Chiariello M, Tamburrini A, Oliviero S, Neri F, Orlandini M, Galvagni F. SNAI1 is upregulated during muscle regeneration and represses FGF21 and ATF3 expression by directly binding their promoters. FASEB J. 2022;36(7):e22401.
6) Migliore L, Galvagni F, Pierantozzi E, Sorrentino V, Rossi D. Allele-specific silencing by RNAi of R92Q and R173W mutations in cardiac troponin T. Exp Biol Med (Maywood). 2022;247(10):805-814.
7) Mitola S, Ravelli C, Corsini M, Gianoncelli A, Galvagni F, Ballmer-Hofer K, Presta M, Grillo E. Production and Biochemical Characterization of Dimeric Recombinant Gremlin-1. Int J Mol Sci. 2022;23(3):1151.
8) Tassone G, Paolino M, Pozzi C, Reale A, Salvini L, Giorgi G, Orlandini M, Galvagni F, Mangani S, Yang X, Carlotti B, Ortica F, Latterini L, Olivucci M, Cappelli A. Xanthopsin-Like Systems via Site-Specific Click-Functionalization of a Retinoic Acid Binding Protein. Chembiochem. 2022;23(1):e202100449.

9) Barbera S, Raucci L, Lugano R, Tosi GM, Dimberg A, Santucci A, Galvagni F, Orlandini M. CD93 Signaling via Rho Proteins Drives Cytoskeletal Remodeling in Spreading Endothelial Cells. Int J Mol Sci. 2021;22(22):12417.
10) Mundo L, Tosi GM, Lazzi S, Pertile G, Parolini B, Neri G, Posarelli M, De Benedetto E, Bacci T, Silvestri E, Siciliano MC, Barbera S, Orlandini M, Greenwood J, Moss SE, Galvagni F. LRG1 Expression Is Elevated in the Eyes of Patients with Neovascular Age-Related Macular Degeneration. Int J Mol Sci. 2021;22(16):8879.
11) Barbera S, Lugano R, Pedalina A, Mongiat M, Santucci A, Tosi GM, Dimberg A, Galvagni F, Orlandini M. The C-type lectin CD93 controls endothelial cell migration via activation of the Rho family of small GTPases. Matrix Biol. 2021;99:1-17.
12) Tosi GM, Giustarini D, Franci L, Minetti A, Imperatore F, Caldi E, Fiorenzani P, Aloisi AM, Sparatore A, Rossi R, Chiariello M, Orlandini M, Galvagni F. Superior Properties of N-Acetylcysteine Ethyl Ester over N-Acetyl Cysteine to Prevent Retinal Pigment Epithelial Cells Oxidative Damage. Int J Mol Sci. 2021;22(2):600.
13) Grieco GE, Sebastiani G, Eandi CM, Neri G, Nigi L, Brusco N, D'Aurizio R, Posarelli M, Bacci T, Benedetto E, Fruschelli M, Orlandini M, Galvagni F, Dotta F, Tosi GM. MicroRNA Expression in the Aqueous Humor of Patients with Diabetic Macular Edema. Int J Mol Sci. 2020;21(19):7328.
14) Giustarini D, Galvagni F, Dalle-Donne I, Milzani A, Lucattelli M, De Cunto G, Bartolini D, Galli F, Santucci A, Rossi R. Anethole Dithiolethione Increases Glutathione in Kidney by Inhibiting γ-Glutamyltranspeptidase: Biochemical Interpretation and Pharmacological Consequences. Oxid Med Cell Longev. 2020;2020:3562972.
15) Tosi GM, Regoli M, Altera A, Galvagni F, Arcuri C, Bacci T, Elia I, Realini G, Orlandini M, Bertelli E. Heat Shock Protein 90 Involvement in the Development of Idiopathic Epiretinal Membranes. Invest Ophthalmol Vis Sci. 2020;61(8):30.
16) Tosi GM, Neri G, Barbera S, Mundo L, Parolini B, Lazzi S, Lugano R, Poletto E, Leoncini L, Pertile G, Mongiat M, Dimberg A, Galvagni F*, Orlandini M*. The Binding of CD93 to Multimerin-2 Promotes Choroidal Neovascularization. Invest Ophthalmol Vis Sci. 2020;61(8):30. (*GF and MO. co-corresponding authors)
17) Barbera S, Nardi F, Elia I, Realini G, Lugano R, Santucci A, Tosi GM, Dimberg A, Galvagni F*, Orlandini M*. The small GTPase Rab5c is a key regulator of trafficking of the CD93/Multimerin-2/β1 integrin complex in endothelial cell adhesion and migration. Cell Commun Signal. 2019;17(1):55. (*GF and MO. co-corresponding authors)
18) Tosi GM, Orlandini M, Galvagni F. The Controversial Role of TGF-β in Neovascular Age-Related Macular Degeneration Pathogenesis. Int J Mol Sci. 2018;19(11):3363.
19) Giustarini D, Galvagni F, Dalle Donne I, Milzani A, Severi FM, Santucci A, Rossi R. N-acetylcysteine ethyl ester as GSH enhancer in human primary endothelial cells: A comparative study with other drugs. Free Radic Biol Med. 2018;126:202-209.
20) Tosi, GM, Neri G, Caldi E, Fusco F, Bacci T, Tarantello A, Nuti E, Marigliani D, Baiocchi S, Traversi C, Barbarino M, Eandi CM, Parolini B, Mundo L, Santucci A, Orlandini M, Galvagni F. TGF-β concentrations and activity are down-regulated in the aqueous humor of patients with neovascular age-related macular degeneration. Scientific Reports. 2018; 8:8053.
21) Galvagni F*, Nardi F, Spiga O, Trezza A, Tarticchio G, Pellicani R, Andreuzzi E, Caldi E, Toti P, Tosi GM, Santucci A, Iozzo RV, Mongiat M, Orlandini M. Dissecting the CD93-Multimerin 2 interaction involved in cell adhesion and migration of the activated endothelium. Matrix Biology. 2017;64:112-127 (*GF and MO. co-corresponding authors).
22) Tosi, GM Barbarino M, Orlandini M, Galvagni F. New molecular targets for the treatment of neovascular age-related macular degeneration. Translational Medicine Reports. 2017;1(3):6819.
23) Giustarini D, Galvagni F, Colombo G, Dalle-Donne I, Milzani A, Aloisi AM, Rossi R.

Determination of protein thiolation index (PTI) as a biomarker of oxidative stress in human serum. Anal Biochem. 2017;538:38-41.
24) Galgano D, Onnis A, Pappalardo E, Galvagni F, Acuto O, Baldari CT. The T cell IFT20 interactome reveals new players in immune synapse assembly. J Cell Sci. 2017;130(6):1110-1121.
25) Tosi GM, Caldi E, Neri G, Nuti E, Marigliani D, Baiocchi S, Traversi C, Cevenini G, Tarantello A, Fusco F, Nardi F, Orlandini M, Galvagni F. HTRA1 and TGF-β1 Concentrations in the Aqueous Humor of Patients With Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2017;58(1):162-167.
26) Tosi GM, Caldi E, Parolini B, Toti P, Neri G, Nardi F, Traversi C, Cevenini G, Marigliani D, Nuti E, Bacci T, Galvagni F*, Orlandini M. CD93 as a Potential Target in Neovascular Age-Related Macular Degeneration. J Cell Physiol. 2017;232(7):1767-1773. (*GF and MO. co-corresponding authors)
27) Millucci L, Bernardini G, Marzocchi B, Braconi D, Geminiani M, Gambassi S, Laschi M, Frediani B, Galvagni F, Orlandini M, Santucci A. Angiogenesis in alkaptonuria. J Inherit Metab Dis. 2016;39(6):801-806.
28) Galvagni F, Nardi F, Maida M, Bernardini G, Vannuccini S, Petraglia F, Santucci A, Orlandini M.. CD93 and dystroglycan cooperation in human endothelial cell adhesion and migration adhesion and migration. Oncotarget. 2016;7(9):10090-103.
29) Giustarini D, Galvagni F, Orlandini M, Fanti P, Rossi R. Immediate stabilization of human blood for delayed quantification of endogenous thiols and disulfides. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1019:51-8.
30) Giustarini D, Galvagni F, Tesei A, Farolfi A, Zanoni M, Pignatta S, Milzani A, Marone IM, Dalle-Donne I, Nassini R, Rossi R (2015). Glutathione, glutathione disulfide, and S-glutathionylated proteins in cell cultures. Free Radic Biol Med. 22;89:972-981.
31) Neri F, Incarnato D, Krepelova A, Dettori D, Rapelli S, Maldotti M, Parlato C, Anselmi F, Galvagni F, Oliviero S. TET1 is controlled by pluripotency-associated factors in ESCs and downmodulated by PRC2 in differentiated cells and tissues. Nucleic Acids Res. 2015;43(14):6814-26.
32) Galvagni F, Neri F. Snai1 represses Nanog to promote embryonic stem cell differentiation. Genomics Data. 2015;4: 82-83
33) Galvagni F*, Lentucci C, Neri F, Dettori D, De Clemente C, Orlandini M, Anselmi F, Rapelli S, Grillo M, Borghi S, Oliviero S*. Snai1 Promotes ESC Exit from the Pluripotency by Direct Repression of Self-Renewal Genes. Stem Cells. 2015;33(3):742-750. (*GF and OS. co-corresponding authors).
34) Orlandini M, Galvagni F, Bardelli M, Rocchigiani M, Lentucci C, Anselmi F, Zippo A, Bini L, Oliviero S. The characterization of a novel monoclonal antibody against CD93 unveils a new antiangiogenic target. Oncotarget. 2014;5(9):2750-60.
35) Galvagni F*, Orlandini M, Oliviero S. Role of the AP-1 transcription factor FOSL1 in endothelial cells adhesion and migration. Cell Adh Migr 2013;7(5):408-11. (*GF and OS. co-corresponding authors).
36) Neri F, Krepelova A, Incarnato D, Maldotti M, Parlato C, Galvagni F, Matarese F, Stunnenberg HG, Oliviero S. Dnmt3L antagonizes DNA methylation at bivalent promoters and favors DNA methylation at gene bodies in ESCs. Cell. 2013;155(1):121-34.
37) Evellin S*, Galvagni F*, Zippo A, Neri F, Orlandini M, Incarnato D, Dettori D, Neubauer S, Kessler H, Wagner EF, Oliviero S. FOSL1 controls the assembly of endothelial cells into capillary tubes by direct repression of alphav and beta3 integrin transcription. Mol Cell Biol. 2013;33(6):1198-209. (*E.S. and G.F. equal contribution).
38) Galvagni F, Baldari CT, Oliviero S, Orlandini M. An apical actin-rich domain drives the establishment of cell polarity during cell adhesion. Histochem Cell Biol. 2012,138(3):419-433.
39) Anselmi F, Orlandini M, Rocchigiani M, De Clemente C, Salameh A, Lentucci C, Oliviero S, Galvagni F. c-ABL modulates MAP kinases activation downstream of VEGFR-2 signaling by direct phosphorylation of the adaptor proteins GRB2 and NCK1. Angiogenesis. 2012;15:187-197.

40) Galvagni F, Pennacchini S, Salameh A, Rocchigiani M, Neri F, Orlandini M, Petraglia F, Gotta S, Sardone GL, Matteucci G, Terstappen GC, Oliviero S. Endothelial cell adhesion to the extracellular matrix induces c-Src-dependent VEGFR-3 phosphorylation without the activation of the receptor intrinsic kinase activity. Circulation Research. 2010;106:1839-1848.
41) Salameh A*, Galvagni F*, Anselmi F, De Clemente C, Orlandini M, Oliviero S. Growth factor stimulation induces cell survival by c-Jun. ATF2-dependent activation of Bcl-XL. J Biol Chem. 2010;285:23096-23104. (*S.A. and G.F. equal contribution).
42) Orlandini M, Nucciotti S, Galvagni F, Bardelli M, Rocchigiani M, Petraglia F, Oliviero S. Morphogenesis of human endothelial cells is inhibited by DAB2 via Src. FEBS Lett. 2008;582(17):2542-2548.
43) Galvagni F, Anselmi F., Salameh A., Rocchigiani M., Orlandini M. and Oliviero S. Vascular endothelial growth factor receptor-3 activity is modulated by its association with caveolin-1 on endothelial membrane. Biochemistry. 2007;46 (13):3998-4005.
44) Salameh A, Galvagni F, Bardelli M., Bussolino F. and Oliviero S. Direct recruitment of CRK and GRB2 to VEGFR-3 induce proliferation, migration and survival of endithelial cells through the activation of ERK, AKT and JNK pathways. Blood. 2005;106(10):3423-3431.
45) Zippo A, De Robertis A, Bardelli M, Galvagni F and Oliviero S. Identification of Flk-1-target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood. 2004;103 (12):4536-44.
46) Chamboredon S, Briggs J, Vial E, Hurault J, Galvagni F, Oliviero S, Bos T, Castellazzi M. v-Jun downregulates the SPARC target gene by binding to the proximal promoter indirectly through Sp1/3. Oncogene. 2003;272(26):4047-61.
47) Galvagni F, Cantini M and Oliviero S. The Utrophin Gene Is Transcriptionally Up-regulated in Regenerating Muscle. J Biol Chem. 2002;277(21):19106-13.
48) Galvagni F, Capo S and Oliviero S. Sp1 and Sp3 physically interact and co-operate with GABP for the activation of the utrophin promoter. J Mol Biol. 2001;306(5):983-994.
49) Plyte S, Boncristiano M, Fattori E, Galvagni F, Rossi Paccani S, Majolini MB, Oliviero S, Ciliberto G, Telford JL, and Baldari CT. Identification and characterization of a novel NFAT1 isoform expressed in mouse brain. J Biol Chem. 2001;276(17):14350-14358.
50) Galvagni F and Oliviero S. Utrophin transcription is activated by an intronic enhancer. J Biol Chem. 2000;275(5), 3168-3172.
51) Galvagni F, Cartocci E and Oliviero S. The dystrophin promoter is negatively regulated by YY1 in undifferentiated muscle cells. J Biol Chem. 1998;273(50):33708-33713.
52) Galvagni F, Lestingi M, Cartocci E and Oliviero S. SRF and protein-mediated DNA bending contribute to transcription of the muscle-specific dystrophin promoter. Mol Cel Biol. 1997;17,:1731-1743.
53) Toscano A, Vitiello L, Comi GP, Galvagni F, Miorin M, Prelle A, Fortunato F, Bardoni A, Mora M, Fiumara A, Falsaperla R, Tomelleri G, Tonin P, Danieli GA, Vita G. Duplication of dystrophin gene and dissimilar clinical phenotype in the same family. Neuromuscolar Disord. 1995;5(6):475-81.
54) Nobile C, Galvagni F, Marchi J, Roberts R, Vitiello L. Genomic organization of the human dystrophin gene across the major deletion hot spot and the 3' region. Genomics. 1995;28:97-100.
55) Kvaloy K, Galvagni F, Brown WRA. The sequence organization of the long arm pseudoautosomal region of the human sex chromosomes. Hum Mol Genet. 1994;3(5):771-778.
56) Galvagni F, Saad FA, Danieli GA, Miorin M, Vitiello L, Mostacciuolo ML, Angelini C. A study on duplications of the dystrophin gene: evidence of a geographical difference in the distribution of breakpoints by intron. Hum Genet. 1994;94:83-87.
57) Saad FA, Galvagni F, Danieli GA. Rapid detection of human dystrophin gene mutations by multiplex semi-quantitative PCR (MSQ PCR). Basic Appl Myol (BAM). 1993;3(3):229-231.
58) Abdel-Meguin IE, Abdel-Salam E, Saad FA, Galvagni F, Miorin M and Danieli GA. Screening

for deletions and duplications in a group of egyptian patients affected with Duchenne muscular dystrophy. Acta cardiomiologica. 1993;5:255-258.
59) Galvagni F, Saad FA, Miorin M, Mostacciuolo ML and Danieli GA. Quantitative PCR screening for intragenic duplication in a large group of DMD/BMD patients. Acta cardiomiologica. 1993:5:303-305.